Optimi Health Secures Ibogaine Supply, Begins Drug Product Development Amid US Prioritization

summarizeSummary

Optimi Health has secured ibogaine supply and is commencing development of finished drug products, capitalizing on recent US executive orders prioritizing ibogaine for accelerated FDA review and expanded patient access.

check_boxKey Events

• Ibogaine Supply Secured

  Optimi Health has secured naturally derived ibogaine from two sources, in both hydrochloride (HCl) and freebase forms.

• Drug Product Development Commences

  Development work on 50mg and 100mg encapsulated ibogaine drug products is anticipated to begin this summer at the company's GMP facility in British Columbia, Canada.

• Strategic Regulatory Alignment

  This initiative aligns with a recent U.S. Executive Order (April 18, 2026) prioritizing ibogaine compounds for accelerated FDA review and expanded patient access, supported by federal funding.

• Canadian Regulatory Advantage

  Ibogaine is not a controlled substance in Canada, positioning Optimi's GMP infrastructure as an advantageous base for compliant manufacture and supply for research and regulated access.

auto_awesomeAnalysis

Optimi Health's move to secure ibogaine supply and commence finished drug product development is a significant strategic expansion. This initiative positions the company to capitalize on a growing market for psychedelic therapies, especially given the recent US Executive Order prioritizing ibogaine for accelerated FDA review and expanded patient access. Leveraging its existing GMP facilities and Canada's favorable regulatory environment for ibogaine, Optimi is diversifying its product pipeline beyond psilocybin and MDMA, potentially opening up a substantial new revenue stream in a high-demand therapeutic area.